TrialBlood2023

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.

V Koneti Rao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.